Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
131.38
-1.36 (-1.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy
April 13, 2023
Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy.
Via
Benzinga
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
April 13, 2023
According to a report, some staffers wanted to reject the highly watched drug.
Via
Investor's Business Daily
Why Is Merck (MRK) Stock Up Today?
April 13, 2023
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda.
Via
InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
April 13, 2023
BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering.
Via
InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
April 13, 2023
Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs.
Via
InvestorPlace
Why Sarepta Therapeutics Stock Is Tumbling Today
April 13, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy...
Via
Benzinga
TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know
March 22, 2023
Via
Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
March 22, 2023
Via
Benzinga
Sarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: Analyst
March 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 13, 2023
Via
Benzinga
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
April 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations
April 10, 2023
San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
April 10, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
April 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
2 Top Growth Stocks That Could Soar This Spring
April 06, 2023
Exciting news on the way for both of these companies could send their stock prices screaming higher.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
April 04, 2023
Via
Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
April 02, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm
March 29, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
March 25, 2023
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.
Via
InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
March 25, 2023
These companies are small now but could grow much larger over time.
Via
The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
March 24, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
March 23, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
March 21, 2023
The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood...
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation
March 21, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
March 17, 2023
Via
Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
March 17, 2023
A market rally is underway, but bank stocks kept tumbling.
Via
Investor's Business Daily
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 17, 2023
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp.
Via
Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
March 17, 2023
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.